Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant

Tyrosine kinase BCR-ABL fusion protein is the driver in patients with chronic myeloid leukemia (CML). The gate-keeper mutation T315I is the most challenging mutant due to its resistance to most tyrosine kinase inhibitors (TKIs). The third generation TKI ponatinib is the only effective TKI to treat C...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Bei, Wang, Chengyan, Shen, Yingying, Pan, Jingxuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833368/
https://www.ncbi.nlm.nih.gov/pubmed/29358661
http://dx.doi.org/10.1038/s41419-017-0075-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833368/
https://www.ncbi.nlm.nih.gov/pubmed/29358661
http://dx.doi.org/10.1038/s41419-017-0075-7

Ejemplares similares